MedTrace Logo

Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and Lymphoma

NCT03272256 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-10-19

No results posted yet for this study

Summary

The main purpose of first-in-human IM156 study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose and recommended phase 2 dose of IM156.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

IM156

Sequential 3+3 design.

Sponsors & Collaborators

  • ImmunoMet Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Sun Young Rha, MD, PhD · Department of oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-09
Primary Completion
2019-12-02
Completion
2020-07-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03272256 on ClinicalTrials.gov